Novel targets in solid tumors: MEK inhibitors.

摘要: Dr. Messersmith is Assistant Professor of Oncology at the Sidney Kimmel Cancer Center Johns Hopkins University in Baltimore, MD, where Hidalgo Associate and Carducci Urology. Eckhardt Medicine Colorado Aurora, Colo. Address correspondence to:Wells Messersmith, Comprehensive Hopkins, CRB 1M88, 1650 Orleans Street, MD 21231; Tel: 410-502-3543; Fax: 410-614-9006; E-mail: wmesser1@jhmi.edu.Abstract: MAPK/ERK kinase (MEK) inhibitors constitute a promising class novel targeted therapies. Although some initial clinical results with these compounds were disappointing, newer agents more advantageous pharmacokinetic pharmacodynamic prop-erties have entered trials. Partial responses been seen patients advanced melanoma pancreatic cancer, along prolonged stable disease several tumor types. Rash, diarrhea, edema, visual disturbances common toxicities. With recent finding that cell lines B-raf mutations are exquisitely sensitive to compounds, possibility genetic-based patient selection indiviualized therapy has raised. Whether predictions will be borne out testing remains seen.